Rafferty Asset Management’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-14,520
Closed -$980K 1085
2023
Q2
$980K Buy
14,520
+4,692
+48% +$1.94M 0.01% 821
2023
Q1
$4.58M Sell
9,828
-553
-5% -$293K 0.03% 400
2022
Q4
$4.16M Buy
10,381
+1,268
+14% +$486K 0.03% 416
2022
Q3
$2.96M Buy
9,113
+3,026
+50% +$975K 0.03% 418
2022
Q2
$1.61M Sell
6,087
-5,000
-45% -$1.28M 0.01% 530
2022
Q1
$3.33M Buy
11,087
+250
+2% +$87.1K 0.02% 483
2021
Q4
$3.82M Sell
10,837
-155
-1% -$48.3K 0.02% 475
2021
Q3
$2.81M Buy
10,992
+6,988
+175% +$2.48M 0.02% 520
2021
Q2
$2.67M Buy
4,004
+213
+6% +$123K 0.02% 552
2021
Q1
$3.29M Buy
3,791
+2,882
+317% +$3.07M 0.02% 428
2020
Q4
$843K Sell
909
-973
-52% -$1.02M 0.01% 552
2020
Q3
$1.94M Buy
1,882
+881
+88% +$948K 0.02% 425
2020
Q2
$1.01M Buy
1,001
+747
+294% +$694K 0.01% 537
2020
Q1
$221K Sell
254
-1,909
-88% -$1.9M 0.01% 502
2019
Q4
$2.32M Sell
2,163
-2,822
-57% -$2.88M 0.04% 338
2019
Q3
$4.61M Buy
4,985
+124
+3% +$136K 0.07% 160
2019
Q2
$5.49M Buy
4,861
+1,246
+34% +$1.36M 0.1% 142
2019
Q1
$4.91M Buy
+3,615
New +$4.9M 0.08% 141

Other funds holding KYNB

Rafferty Asset Management's KYNB Position: Q3 2023 in Review

Rafferty Asset Management sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 14,520 shares — an estimated $980K sold.

Rafferty Asset Management first reported a position in KYNB in Q1 2019 and held it in 18 quarters. The position peaked at $5.49M in Q2 2019. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Rafferty Asset Management reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 14,520 Kyntra Bio shares in Q3 2023, an estimated $980K.
  • Rafferty Asset Management first reported a position in Kyntra Bio in Q1 2019 and held it in 18 quarters.
  • Rafferty Asset Management's Kyntra Bio position peaked at $5.49M in Q2 2019.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Rafferty Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.